Clinical Trial

Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura

Study acronym: DarTTP
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 14, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators aim at collecting evidence on a larger number of patients through a collaborative, international study.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Recruiting 2026-04-15
Trial Details
NCT Number NCT07513948
Lead Sponsor Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Conditions Thrombotic Thrombocytopenic Purpura, Acquired
Enrollment 40 participants
Start Date 2025-10-01
Primary Completion 2026-06 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-14